US3812854A
(en)
|
1972-10-20 |
1974-05-28 |
A Michaels |
Ultrasonic nebulizer
|
US4501729A
(en)
|
1982-12-13 |
1985-02-26 |
Research Corporation |
Aerosolized amiloride treatment of retained pulmonary secretions
|
US5286634A
(en)
|
1989-09-28 |
1994-02-15 |
Stadler Joan K |
Synergistic method for host cell transformation
|
US6153737A
(en)
|
1990-01-11 |
2000-11-28 |
Isis Pharmaceuticals, Inc. |
Derivatized oligonucleotides having improved uptake and other properties
|
US5214136A
(en)
|
1990-02-20 |
1993-05-25 |
Gilead Sciences, Inc. |
Anthraquinone-derivatives oligonucleotides
|
US5138045A
(en)
|
1990-07-27 |
1992-08-11 |
Isis Pharmaceuticals |
Polyamine conjugated oligonucleotides
|
DE69127826T2
(de)
|
1990-12-17 |
1998-04-09 |
Minnesota Mining & Mfg |
Inhalationsgerät
|
US6335434B1
(en)
|
1998-06-16 |
2002-01-01 |
Isis Pharmaceuticals, Inc., |
Nucleosidic and non-nucleosidic folate conjugates
|
GB9127376D0
(en)
|
1991-12-24 |
1992-02-19 |
Wellcome Found |
Amidino derivatives
|
MX9301943A
(es)
|
1992-04-02 |
1994-08-31 |
Smithkline Beecham Corp |
Compuestos.
|
CA2135646A1
(en)
|
1992-05-11 |
1993-11-25 |
Kenneth G. Draper |
Method and reagent for inhibiting viral replication
|
US5977343A
(en)
|
1992-05-14 |
1999-11-02 |
Ribozyme Pharmaceuticals, Inc. |
Synthesis, deprotection, analysis and purification of RNA and ribozymes
|
US6582728B1
(en)
|
1992-07-08 |
2003-06-24 |
Inhale Therapeutic Systems, Inc. |
Spray drying of macromolecules to produce inhaleable dry powders
|
WO1994002595A1
(en)
|
1992-07-17 |
1994-02-03 |
Ribozyme Pharmaceuticals, Inc. |
Method and reagent for treatment of animal diseases
|
US6235886B1
(en)
|
1993-09-03 |
2001-05-22 |
Isis Pharmaceuticals, Inc. |
Methods of synthesis and use
|
WO1994021229A1
(en)
|
1993-03-17 |
1994-09-29 |
Minnesota Mining And Manufacturing Company |
Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid
|
CA2170869C
(en)
|
1993-09-03 |
1999-09-14 |
Phillip Dan Cook |
Amine-derivatized nucleosides and oligonucleosides
|
US5624803A
(en)
|
1993-10-14 |
1997-04-29 |
The Regents Of The University Of California |
In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
|
US5902880A
(en)
|
1994-08-19 |
1999-05-11 |
Ribozyme Pharmaceuticals, Inc. |
RNA polymerase III-based expression of therapeutic RNAs
|
US6051256A
(en)
|
1994-03-07 |
2000-04-18 |
Inhale Therapeutic Systems |
Dispersible macromolecule compositions and methods for their preparation and use
|
US6447796B1
(en)
|
1994-05-16 |
2002-09-10 |
The United States Of America As Represented By The Secretary Of The Army |
Sustained release hydrophobic bioactive PLGA microspheres
|
EP0957087B1
(en)
|
1994-06-15 |
2002-12-04 |
The Wellcome Foundation Limited |
Intermediates useful in the preparation of enzyme inhibitors
|
US6146886A
(en)
|
1994-08-19 |
2000-11-14 |
Ribozyme Pharmaceuticals, Inc. |
RNA polymerase III-based expression of therapeutic RNAs
|
US5753613A
(en)
|
1994-09-30 |
1998-05-19 |
Inex Pharmaceuticals Corporation |
Compositions for the introduction of polyanionic materials into cells
|
US5885613A
(en)
|
1994-09-30 |
1999-03-23 |
The University Of British Columbia |
Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
|
US5820873A
(en)
|
1994-09-30 |
1998-10-13 |
The University Of British Columbia |
Polyethylene glycol modified ceramide lipids and liposome uses thereof
|
WO1996018736A2
(en)
|
1994-12-13 |
1996-06-20 |
Ribozyme Pharmaceuticals, Inc. |
Method and reagent for treatment of arthritic conditions, induction of graft tolerance and reversal of immune responses
|
ES2292526T3
(es)
|
1995-04-14 |
2008-03-16 |
Smithkline Beecham Corporation |
Procedimiento para la preparacion de un inhalador dosificador.
|
US7422902B1
(en)
|
1995-06-07 |
2008-09-09 |
The University Of British Columbia |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
US5981501A
(en)
|
1995-06-07 |
1999-11-09 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating plasmids in lipid bilayers
|
IL122290A0
(en)
|
1995-06-07 |
1998-04-05 |
Inex Pharmaceuticals Corp |
Lipid-nucleic acid complex its preparation and use
|
US5705385A
(en)
|
1995-06-07 |
1998-01-06 |
Inex Pharmaceuticals Corporation |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
US5889136A
(en)
|
1995-06-09 |
1999-03-30 |
The Regents Of The University Of Colorado |
Orthoester protecting groups in RNA synthesis
|
US5998203A
(en)
|
1996-04-16 |
1999-12-07 |
Ribozyme Pharmaceuticals, Inc. |
Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
|
MY117948A
(en)
|
1997-01-13 |
2004-08-30 |
Glaxo Group Ltd |
Nitride oxide synthase inhibitors.
|
US6001311A
(en)
|
1997-02-05 |
1999-12-14 |
Protogene Laboratories, Inc. |
Apparatus for diverse chemical synthesis using two-dimensional array
|
US6126919A
(en)
|
1997-02-07 |
2000-10-03 |
3M Innovative Properties Company |
Biocompatible compounds for pharmaceutical drug delivery systems
|
US6235310B1
(en)
|
1997-04-04 |
2001-05-22 |
Valentis, Inc. |
Methods of delivery using cationic lipids and helper lipids
|
US6835395B1
(en)
|
1997-05-14 |
2004-12-28 |
The University Of British Columbia |
Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles
|
CA2289702C
(en)
|
1997-05-14 |
2008-02-19 |
Inex Pharmaceuticals Corp. |
High efficiency encapsulation of charged therapeutic agents in lipid vesicles
|
DE19723722A1
(de)
|
1997-05-30 |
1998-12-10 |
Schering Ag |
Nichtsteroidale Gestagene
|
TW533865U
(en)
|
1997-06-10 |
2003-05-21 |
Glaxo Group Ltd |
Dispenser for dispensing medicament and actuation indicating device
|
WO1998058630A1
(en)
|
1997-06-23 |
1998-12-30 |
Sequus Pharmaceuticals, Inc. |
Liposome-entrapped polynucleotide composition and method
|
US6395713B1
(en)
|
1997-07-23 |
2002-05-28 |
Ribozyme Pharmaceuticals, Inc. |
Compositions for the delivery of negatively charged molecules
|
TW589189B
(en)
|
1997-08-04 |
2004-06-01 |
Scras |
Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis
|
US6565885B1
(en)
|
1997-09-29 |
2003-05-20 |
Inhale Therapeutic Systems, Inc. |
Methods of spray drying pharmaceutical compositions
|
WO1999016766A1
(fr)
|
1997-10-01 |
1999-04-08 |
Kyowa Hakko Kogyo Co., Ltd. |
Derives de benzodioxole
|
US6054576A
(en)
|
1997-10-02 |
2000-04-25 |
Ribozyme Pharmaceuticals, Inc. |
Deprotection of RNA
|
US6506559B1
(en)
|
1997-12-23 |
2003-01-14 |
Carnegie Institute Of Washington |
Genetic inhibition by double-stranded RNA
|
WO1999034831A1
(en)
|
1998-01-05 |
1999-07-15 |
University Of Washington |
Enhanced transport using membrane disruptive agents
|
US6410328B1
(en)
|
1998-02-03 |
2002-06-25 |
Protiva Biotherapeutics Inc. |
Sensitizing cells to compounds using lipid-mediated gene and compound delivery
|
US6506766B1
(en)
|
1998-02-13 |
2003-01-14 |
Abbott Laboratories |
Glucocortiocoid-selective antinflammatory agents
|
US6111086A
(en)
|
1998-02-27 |
2000-08-29 |
Scaringe; Stephen A. |
Orthoester protecting groups
|
CA2323771A1
(en)
|
1998-03-14 |
1999-09-23 |
Byk Gulden Lomberg Chemische Fabrik Gmbh |
Phthalazinone pde iii/iv inhibitors
|
WO1999054459A2
(en)
|
1998-04-20 |
1999-10-28 |
Ribozyme Pharmaceuticals, Inc. |
Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
|
GB9811599D0
(en)
|
1998-05-30 |
1998-07-29 |
Glaxo Group Ltd |
Nitric oxide synthase inhibitors
|
GB9827152D0
(en)
|
1998-07-03 |
1999-02-03 |
Devgen Nv |
Characterisation of gene function using double stranded rna inhibition
|
EP1096921B1
(en)
|
1998-07-20 |
2003-04-16 |
Protiva Biotherapeutics Inc. |
Liposomal encapsulated nucleic acid-complexes
|
US6995259B1
(en)
|
1998-10-23 |
2006-02-07 |
Sirna Therapeutics, Inc. |
Method for the chemical synthesis of oligonucleotides
|
US6390291B1
(en)
|
1998-12-18 |
2002-05-21 |
Smithkline Beecham Corporation |
Method and package for storing a pressurized container containing a drug
|
US6119853A
(en)
|
1998-12-18 |
2000-09-19 |
Glaxo Wellcome Inc. |
Method and package for storing a pressurized container containing a drug
|
US6352152B1
(en)
|
1998-12-18 |
2002-03-05 |
Smithkline Beecham Corporation |
Method and package for storing a pressurized container containing a drug
|
US6315112B1
(en)
|
1998-12-18 |
2001-11-13 |
Smithkline Beecham Corporation |
Method and package for storing a pressurized container containing a drug
|
WO2000044914A1
(en)
|
1999-01-28 |
2000-08-03 |
Medical College Of Georgia Research Institute, Inc. |
Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
|
DE19956568A1
(de)
|
1999-01-30 |
2000-08-17 |
Roland Kreutzer |
Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
|
CA2365625A1
(en)
|
1999-03-10 |
2000-09-14 |
Phogen Limited |
Delivery of substances to cells
|
US6576224B1
(en)
|
1999-07-06 |
2003-06-10 |
Sinuspharma, Inc. |
Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
|
DE60026030T2
(de)
|
1999-07-14 |
2006-08-10 |
Alza Corp., Mountain View |
Neutrales lipopolymer und liposomale zusammensetzungen daraus
|
ES2165768B1
(es)
|
1999-07-14 |
2003-04-01 |
Almirall Prodesfarma Sa |
Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
|
CO5180649A1
(es)
|
1999-09-01 |
2002-07-30 |
Abbott Lab |
Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes
|
CA2386270A1
(en)
|
1999-10-15 |
2001-04-26 |
University Of Massachusetts |
Rna interference pathway genes as tools for targeted genetic interference
|
GB9927444D0
(en)
|
1999-11-19 |
2000-01-19 |
Cancer Res Campaign Tech |
Inhibiting gene expression
|
OA11558A
(en)
|
1999-12-08 |
2004-06-03 |
Advanced Medicine Inc |
Beta 2-adrenergic receptor agonists.
|
NZ523958A
(en)
|
2000-08-05 |
2004-11-26 |
Glaxo Group Ltd |
17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derviative as anti-inflammatory agents
|
WO2002018405A2
(en)
|
2000-09-01 |
2002-03-07 |
Ribozyme Pharmaceuticals, Incorporated |
Methods for synthesizing nucleosides, nucleoside derivatives and non-nucleoside derivatives
|
IL155093A0
(en)
|
2000-09-29 |
2003-10-31 |
Glaxo Group Ltd |
Morpholin-acetamide derivatives for the treatment on inflammatory diseases
|
US6998115B2
(en)
|
2000-10-10 |
2006-02-14 |
Massachusetts Institute Of Technology |
Biodegradable poly(β-amino esters) and uses thereof
|
US7427394B2
(en)
|
2000-10-10 |
2008-09-23 |
Massachusetts Institute Of Technology |
Biodegradable poly(β-amino esters) and uses thereof
|
GB0031179D0
(en)
|
2000-12-21 |
2001-01-31 |
Glaxo Group Ltd |
Nitric oxide synthase inhibitors
|
US20020130430A1
(en)
|
2000-12-29 |
2002-09-19 |
Castor Trevor Percival |
Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products
|
US6484903B2
(en)
|
2001-01-09 |
2002-11-26 |
Riverwood International Corporation |
Carton with an improved dispensing feature in combination with a unique handle
|
US6401408B1
(en)
|
2001-01-29 |
2002-06-11 |
Plastics Research Corporation |
Molded plastic stake with multiple shoulders
|
GB0103630D0
(en)
|
2001-02-14 |
2001-03-28 |
Glaxo Group Ltd |
Chemical compounds
|
WO2002070490A1
(en)
|
2001-03-08 |
2002-09-12 |
Glaxo Group Limited |
Agonists of beta-adrenoceptors
|
US20050164220A1
(en)
|
2001-03-19 |
2005-07-28 |
Decode Genetics Ehf. |
Susceptibility gene for human stroke: method of treatment
|
WO2004028341A2
(en)
|
2001-03-19 |
2004-04-08 |
Decode Genetics Ehf. |
Susceptibility gene for human stroke; methods of treatment
|
ES2375333T3
(es)
|
2001-03-20 |
2012-02-28 |
Trudell Medical International |
Aparato nebulizador.
|
EP1370521B1
(en)
|
2001-03-22 |
2007-12-19 |
Glaxo Group Limited |
Formanilide derivatives as beta2-adrenoreceptor agonists
|
US20040049022A1
(en)
*
|
2001-04-24 |
2004-03-11 |
Nyce Jonathan W. |
Composition & methods for treatment and screening
|
WO2002088167A1
(en)
|
2001-04-30 |
2002-11-07 |
Glaxo Group Limited |
Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
|
WO2002087541A1
(en)
|
2001-04-30 |
2002-11-07 |
Protiva Biotherapeutics Inc. |
Lipid-based formulations for gene transfer
|
US20050187174A1
(en)
*
|
2001-05-18 |
2005-08-25 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA)
|
US20050048529A1
(en)
*
|
2002-02-20 |
2005-03-03 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA)
|
US7090830B2
(en)
|
2001-05-24 |
2006-08-15 |
Alexza Pharmaceuticals, Inc. |
Drug condensation aerosols and kits
|
DE60227254D1
(de)
|
2001-06-12 |
2008-08-07 |
Glaxo Group Ltd |
Neue anti inflammatorische 17.alpha.-heterozyklische ester von 17.beta.-carbothioat androstan derivativen
|
US20030158133A1
(en)
|
2001-08-01 |
2003-08-21 |
Movsesian Matthew A. |
Isoform-selective inhibitors and activators of PDE3 cyclic nucleotide phosphodiesterases
|
SI1425001T1
(sl)
|
2001-09-14 |
2009-04-30 |
Glaxo Group Ltd Glaxo Welcome |
Fenetanolaminski derivati za zdravljenje respiratornih bolezni
|
US20050191627A1
(en)
|
2001-09-28 |
2005-09-01 |
Incyte Corporation |
Enzymes
|
FR2830766B1
(fr)
|
2001-10-12 |
2004-03-12 |
Optis France Sa |
Dispositif de delivrance de medicaments par iontophorese transpalpebrale
|
FR2830767B1
(fr)
|
2001-10-12 |
2004-03-12 |
Optis France Sa |
Dispositif de delivrance de medicaments par iontophorese ou electroporation introculaire
|
WO2003042160A1
(en)
|
2001-11-13 |
2003-05-22 |
Theravance, Inc. |
Aryl aniline beta-2 adrenergic receptor agonists
|
AUPR894201A0
(en)
|
2001-11-19 |
2001-12-13 |
Women's And Children's Hospital |
Respiratory delivery for gene therapy and lentiviral delivery particle
|
US7060498B1
(en)
|
2001-11-28 |
2006-06-13 |
Genta Salus Llc |
Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
|
US7141540B2
(en)
|
2001-11-30 |
2006-11-28 |
Genta Salus Llc |
Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
|
US20050118594A1
(en)
|
2001-12-14 |
2005-06-02 |
Chawla Narinder K. |
Enzymes
|
AU2003202216A1
(en)
|
2002-01-14 |
2003-07-30 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof
|
WO2003061651A1
(en)
|
2002-01-22 |
2003-07-31 |
The Regents Of The University Of California |
Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
|
GB0204719D0
(en)
|
2002-02-28 |
2002-04-17 |
Glaxo Group Ltd |
Medicinal compounds
|
ATE381333T1
(de)
|
2002-03-26 |
2008-01-15 |
Boehringer Ingelheim Pharma |
Glucocorticoid-mimetika, deren herstellung, pharmazeutische zusammensetzungen und verwendung
|
US7268152B2
(en)
|
2002-03-26 |
2007-09-11 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
|
JP2005529860A
(ja)
|
2002-03-27 |
2005-10-06 |
グラクソ グループ リミテッド |
ジアミノ酸−アミノ酸−ポリアミンに基づいたジェミニ界面活性剤化合物
|
DE10215316C1
(de)
|
2002-04-02 |
2003-12-18 |
Schering Ag |
Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer
|
CA2481320A1
(en)
|
2002-04-11 |
2003-10-23 |
Merck & Co., Inc. |
1h-benzo[f]indazol-5-yl derivatives as selective glucocorticoid receptor modulators
|
DE60318193T2
(de)
|
2002-04-25 |
2008-12-04 |
Glaxo Group Ltd., Greenford |
Phenethanolaminderivate
|
US7186864B2
(en)
|
2002-05-29 |
2007-03-06 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
|
US7074806B2
(en)
|
2002-06-06 |
2006-07-11 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
|
WO2004003145A2
(en)
|
2002-06-28 |
2004-01-08 |
Nastech Pharmaceutical Company Inc. |
Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
|
EP1521733B1
(en)
|
2002-07-08 |
2014-08-20 |
Pfizer Products Inc. |
Modulators of the glucocorticoid receptor
|
US6989442B2
(en)
|
2002-07-12 |
2006-01-24 |
Sirna Therapeutics, Inc. |
Deprotection and purification of oligonucleotides and their derivatives
|
WO2004009017A2
(en)
|
2002-07-18 |
2004-01-29 |
Bristol-Myers Squibb Company |
Modulators of the glucocorticoid receptor and method
|
GB0217225D0
(en)
|
2002-07-25 |
2002-09-04 |
Glaxo Group Ltd |
Medicinal compounds
|
WO2004018429A2
(en)
|
2002-08-21 |
2004-03-04 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
|
GB0220730D0
(en)
|
2002-09-06 |
2002-10-16 |
Glaxo Group Ltd |
Medicinal compounds
|
NZ538515A
(en)
|
2002-09-16 |
2007-04-27 |
Glaxo Group Ltd |
Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors
|
GB0230045D0
(en)
|
2002-12-23 |
2003-01-29 |
Glaxo Group Ltd |
Compounds
|
JP4520309B2
(ja)
|
2002-09-20 |
2010-08-04 |
メルク・シャープ・エンド・ドーム・コーポレイション |
選択的糖質コルチコイド受容体調節剤としてのオクタヒドロ−2−H−ナフト[1,2−f]インドール−4−カルボキサミド誘導体
|
WO2004037807A2
(en)
|
2002-10-22 |
2004-05-06 |
Glaxo Group Limited |
Medicinal arylethanolamine compounds
|
US8133903B2
(en)
|
2003-10-21 |
2012-03-13 |
Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center |
Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases
|
GB0225030D0
(en)
|
2002-10-28 |
2002-12-04 |
Glaxo Group Ltd |
Medicinal compounds
|
CA2503588A1
(en)
|
2002-10-28 |
2004-05-06 |
Glaxo Group Limited |
Phenethanolamine derivative for the treatment of respiratory diseases
|
GB0225540D0
(en)
|
2002-11-01 |
2002-12-11 |
Glaxo Group Ltd |
Medicinal compounds
|
GB0225535D0
(en)
|
2002-11-01 |
2002-12-11 |
Glaxo Group Ltd |
Medicinal compounds
|
TW562704B
(en)
|
2002-11-12 |
2003-11-21 |
Purzer Pharmaceutical Co Ltd |
Ultrasonic atomizer device for generating high contents of sub-micron atomized droplets
|
WO2006006948A2
(en)
*
|
2002-11-14 |
2006-01-19 |
Dharmacon, Inc. |
METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
|
DE602004028587D1
(de)
*
|
2003-01-16 |
2010-09-23 |
Univ Pennsylvania |
ZUSAMMENSETZUNGEN UND VERFAHREN ZUR siRNA-HEMMUNG VON ICAM-1
|
WO2004080887A1
(en)
|
2003-03-07 |
2004-09-23 |
Massachusetts Institute Of Technology |
Three dimensional mecrofabrication
|
TWI328009B
(en)
|
2003-05-21 |
2010-08-01 |
Glaxo Group Ltd |
Quinoline derivatives as phosphodiesterase inhibitors
|
GB0316290D0
(en)
|
2003-07-11 |
2003-08-13 |
Glaxo Group Ltd |
Novel compounds
|
WO2005007196A2
(en)
|
2003-07-16 |
2005-01-27 |
Protiva Biotherapeutics, Inc. |
Lipid encapsulated interfering rna
|
KR101164256B1
(ko)
|
2003-09-15 |
2012-07-10 |
프로티바 바이오쎄라퓨틱스, 인코포레이티드 |
폴리에틸렌글리콜 개질된 지질 화합물 및 그의 용도
|
US7943179B2
(en)
|
2003-09-23 |
2011-05-17 |
Massachusetts Institute Of Technology |
pH triggerable polymeric particles
|
US7579455B2
(en)
|
2003-09-29 |
2009-08-25 |
Topigen Pharmaceutique Inc. |
Oligonucleotide compositions and methods for treating disease including inflammatory conditions
|
CN1901958B
(zh)
|
2003-11-03 |
2011-03-09 |
葛兰素集团有限公司 |
流体分配装置
|
JP5059411B2
(ja)
|
2003-12-19 |
2012-10-24 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
短鎖干渉rnaの細胞トランスフェクティング処方物、関連する組成物および作製方法ならびに使用
|
MXPA06012076A
(es)
|
2004-04-20 |
2007-01-25 |
Nastech Pharm Co |
Metodos y composiciones para mejorar el suministro de arn bicatenario o un acido nucleico hibrido bicatenario para regular la expresion genetica en celulas de mamifero.
|
EP1750673B1
(en)
|
2004-05-17 |
2009-12-02 |
Tekmira Pharmaceuticals Corporation |
Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
|
WO2006000398A1
(en)
|
2004-06-28 |
2006-01-05 |
Glaxo Group Limited |
2,3-benzoxazin derivatives as non-steroidal glucocorticoid receptor modulators
|
WO2006000401A1
(en)
|
2004-06-28 |
2006-01-05 |
Glaxo Group Limited |
Substituted oxazines as glucocorticoid receptor modulators
|
US20060019258A1
(en)
|
2004-07-20 |
2006-01-26 |
Illumina, Inc. |
Methods and compositions for detection of small interfering RNA and micro-RNA
|
GB0418045D0
(en)
|
2004-08-12 |
2004-09-15 |
Glaxo Group Ltd |
Compounds
|
US20060062758A1
(en)
|
2004-09-21 |
2006-03-23 |
Nastech Pharmaceutical Comapny Inc. |
Tight junction modulator peptide PN159 for enhanced mucosal delivery of therapeutic compounds
|
US20090124588A1
(en)
|
2005-01-10 |
2009-05-14 |
Glaxo Group Limited |
Androstane 17-Alpha-Carbonate for Use in the Treatment of Inflammatory and Allergic Conditions
|
WO2006072599A2
(en)
|
2005-01-10 |
2006-07-13 |
Glaxo Group Limited |
Androstane 17-alpha carbonate derivatives for use in the treatment of allergic and inflammatory conditions
|
WO2008137776A2
(en)
*
|
2007-05-02 |
2008-11-13 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of cyclic nucleotide type 4 phosphodiesterase (pde4b) gene expression using short interfering nucleic acid (sina)
|